Featured Research

from universities, journals, and other organizations

Risk calculator developed for venous thromboses

Date:
August 14, 2013
Source:
Medical University of Vienna
Summary:
In Austria, around 15,000 people a year develop a venous thrombosis, the occlusion of a vein that can result in a pulmonary embolism. People who have survived one thrombosis or pulmonary embolism are at risk of the event happening again. Researchers have now developed a “risk calculator” that enables doctors to estimate this risk more accurately.

In Austria, around 15,000 people a year develop a venous thrombosis, the occlusion of a vein that can result in a pulmonary embolism. A clot breaks free from a vein and travels via the bloodstream to the lungs, where it blocks vessels. People who have survived one thrombosis or pulmonary embolism are at risk of the event happening again. Researchers at the MedUni Vienna have now developed a "risk calculator" that enables doctors to estimate this risk more accurately.

The new prediction model (known as the Vienna Prediction Model) will be used at the anticoagulant clinic within the University Department of Internal Medicine I at the MedUni Vienna and the Vienna General Hospital and works on the basis of three key factors: "The patient's gender, the location of the thrombosis and a bio-marker known as the D-dimer," explains Sabine Eichinger-Hasenauer from the University Department of Internal Medicine I.

D-dimers are the products of protein separation. The D-dimer level in the blood is of major significance in the diagnosis or exclusion of deep venous thrombosis and pulmonary embolisms, but also in predicting the risk of the condition recurring.

World's largest thrombosis study The recurrence of a venous thrombosis or pulmonary embolism can only be prevented through intensive treatment with clot-preventing medications. Many patients are therefore advised to take long-term therapy. This therapy, however, means the daily and in some cases lifelong consumption of medications which also entail a major risk of bleeding, which can sometimes even be fatal.

With the risk calculator developed as part of the world's largest study on thrombosis, the Austrian Study on Recurrent Venous Thromboembolism (AUREC), it is now possible to estimate -- and shorten -- the duration of treatment more precisely and forecast the risk of thrombosis or embolism recurring more accurately. Shorter courses of treatment with clot-preventing medications are then possible, thereby reducing the risk of bleeding.

The presentation of the results of the current study at the MedUni Vienna, for which test subjects are currently still being recruited (for information, call 40 400 -- 4496/Lisbeth Eischer, University Department of Internal Medicine I), was also one of the most well-attended presentations at the Congress of the International Society on Thrombosis and Haemostasis held last July in Amsterdam.


Story Source:

The above story is based on materials provided by Medical University of Vienna. Note: Materials may be edited for content and length.


Cite This Page:

Medical University of Vienna. "Risk calculator developed for venous thromboses." ScienceDaily. ScienceDaily, 14 August 2013. <www.sciencedaily.com/releases/2013/08/130814100158.htm>.
Medical University of Vienna. (2013, August 14). Risk calculator developed for venous thromboses. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2013/08/130814100158.htm
Medical University of Vienna. "Risk calculator developed for venous thromboses." ScienceDaily. www.sciencedaily.com/releases/2013/08/130814100158.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins